Argus downgraded Novo Nordisk (NVO) to Hold from Buy.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- LLY, PFE: Eli Lilly’s Mounjaro, Pfizer’s Cancer Drug Added to China’s State Insurance List
- Mixed options sentiment in Novo Nordisk with shares up 0.39%
- Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues
- Eli Lilly price target raised to $1,163 from $1,036 at Guggenheim
- Novo Nordisk price target lowered to $42 from $43 at Morgan Stanley